Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: A meta-analysis of randomized trials

American Heart Journal

Volumn 148, Issue 6, 2004, Pages 990-997

  Schleinitz, Mark D ^a   Olkin, Ingram ^b   Heidenreich, Paul A ^c  

^a RHODE ISLAND HOSPITAL   (United States)

^b STANFORD UNIVERSITY   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CILOSTAZOL; CLOPIDOGREL; TICLOPIDINE; WARFARIN;

ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; HEART DISEASE; HUMAN; META ANALYSIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RISK ASSESSMENT; THROMBOSIS;

ANTICOAGULANTS; ASPIRIN; CORONARY THROMBOSIS; DRUG THERAPY, COMBINATION; HUMANS; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; STENTS; TETRAZOLES; TICLOPIDINE; WARFARIN;

EID: 10644264277     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.03.066     Document Type: Article

References (51)

1. Sigwart U., Puel J., Mirkovitch V., et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 316:1987;701-706
2. Schuhlen H., Kastrati A., Dirschinger J., et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation. 98:1998;104-111
3. Orford J.L., Lennon R., Melby S., et al. Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. J Am Coll Cardiol. 40:2002;1567-1572
4. Serruys P.W., Strauss B.H., Beatt K.J., et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med. 324:1991;13-17
5. Mak K.H., Belli G., Ellis S.G., et al. Subacute stent thrombosis: evolving issues and current concepts. J Am Coll Cardiol. 27:1996;494-503
6. Serruys P.W., de Jaegere P., Kiemeneij F., et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 331:1994;489-495
7. Fischman D.L., Leon M.B., Baim D.S., et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 331:1994;496-501
8. Leon M.B., Baim D.S., Popma J.J., et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 339:1998;1665-1671
9. Schomig A., Neumann F.J., Kastrati A., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 334:1996;1084-1089
10. Urban P., Macaya C., Rupprecht H.J., et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation. 98:1998;2126-2132
11. Bertrand M.E., Legrand V., Boland J., et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation. 98:1998;1597-1603
12. Foussas S., Alexopoulos D., Stefanadis C., et al. Antiplatelet is superior to anticoagulant treatment after coronary stenting: fewer coronary and other events within 30 days after stenting. Angiology. 51:2000;289-294
13. Gent M., Blakely J.A., Easton J.D., et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1:1989;1215-1220
14. Bennett C.L., Weinberg P.D., Rozenberg-Ben-Dror K., et al. Thrombotic thrombocytopenic purpura associated with ticlopidine A review of 60 cases. Ann Intern Med. 128:1998;541-544
15. Iqbal M., Goenka P., Young M.F., et al. Ticlopidine-induced cholestatic hepatitis: report of three cases and review of the literature. Dig Dis Sci. 43:1998;2223-2226
16. Muller C., Buttner H.J., Petersen J., et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation. 101:2000;590-593
17. Bertrand M.E., Rupprecht H.J., Urban P., et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation. 102:2000;624-629
18. Taniuchi M., Kurz H.I., Lasala J.M. Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. Circulation. 104:2001;539-543
19. Piamsomboon C., Laothavorn P., Chatlaong B., et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin after coronary stent implantation: 1 and 6-month follow-up. J Med Assoc Thai. 84:2001;1701-1707
20. Kunishima T., Musha H., Eto F., et al. A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. Clin Ther. 19:1997;1058-1066
21. Park S.W., Lee C.W., Kim H.S., et al. Comparison of cilostazol versus ticlopidine therapy after stent implantation. Am J Cardiol. 84:1999;511-514
22. Yoon Y., Shim W.H., Lee D.H., et al. Usefulness of cilostazol versus ticlopidine in coronary artery stenting. Am J Cardiol. 84:1999;1375-1380
23. Ochiai M., Eto K., Takeshita S., et al. Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction. Am J Cardiol. 84:1999;1074-1076
24. Sekiya M., Funada J., Watanabe K., et al. Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am J Cardiol. 82:1998;144-147
25. Kozuma K., Hara K., Yamasaki M., et al. Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. Am Heart J. 141:2001;124-130
26. Kamishirado H., Inoue T., Mizoguchi K., et al. Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restensosis. Am Heart J. 144:2002;303-308
27. Gleser L.J., Olkin I. Meta-analysis for 2×2 tables with multiple treatment groups. Stangl D., Berry D. Meta-analysis in medicine and health policy. 2000.;Marcel Dekker, New York, NY. p. 179-89
28. Hall P., Nakamura S., Maiello L., et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation. 93:1996;215-222
29. Mishkel G.J., Aguirre F.V., Ligon R.W., et al. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. J Am Coll Cardiol. 34:1999;1884-1890
30. Dangas G., Mehran R., Abizaid A.S., et al. Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. Am J Cardiol. 87:2001;470-472
31. Calver A.L., Blows L.J., Harmer S., et al. Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents. Am Heart J. 140:2000;483-491
32. Berger P.B., Bell M.R., Rihal C.S., et al. Clopidogrel versus ticlopidine after intracoronary stent placement. J Am Coll Cardiol. 34:1999;1891-1894
33. Moussa I., Oetgen M., Roubin G., et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation. 99:1999;2364-2366
34. Pache J., Kastrati A., Mehilli J., et al. Clopidogrel therapy in patients undergoing coronary stenting: value of a high-loading-dose regimen. Catheter Cardiovasc Interv. 55:2002;436-441
35. Tanabe Y., Ito E., Nakagawa I., et al. Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine. Int J Cardiol. 78:2001;285-291
36. L'Allier P.L., Aronow H.D., Cura F.A., et al. Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting. Can J Cardiol. 19:2003;1041-1046
37. Bhatt D., Bertrand M., Berger P., et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol. 39:2002;9-14
38. Dawson D.L., Cutler B.S., Meissner M.H., et al. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation. 98:1998;678-686
39. Ikeda Y., Kikuchi M., Murakami H., et al. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo Randomized, double-blind cross-over study. Arzneimittelforschung. 37:1987;563-566
40. Park S.J., Shim W.H., Ho D.S., et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med. 348:2003;1537-1545
41. Berger P.B., Bell M.R., Hasdai D., et al. Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement. Circulation. 99:1999;248-253
42. Schuhlen H., Kastrati A., Pache J., et al. Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen. J Am Coll Cardiol. 37:2001;2066-2073
43. Steinhubl S.R., Berger P.B., Mann J.T. 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 288:2002;2411-2420
44. Park S., Lee C.W., Kim H., et al. Effects of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol. 86:2000;499-503
45. Bennett C.L., Connors J.M., Carwile J.M., et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 342:2000;1773-1777
46. Bennett C.L., Connors J.M., Moake J.L. N Engl J Med. 343:2000;1193-1194
47. Packer M., Carver J.R., Rodeheffer R.J., et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE study research group. N Engl J Med. 325:1991;1468-1475
48. Cone J., Wang S., Tandon N., et al. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J Cardiovasc Pharmacol. 34:1999;497-504
49. Gamssari F., Mahmood H., Ho J.S., et al. Rapid ventricular tachycardias associated with cilostazol use. Tex Heart Inst J. 29:2002;140-142
50. Pratt C.M. Analysis of the cilostazol safety database. Am J Cardiol. 87:2001;28D-33D
51. Drug Topics Red Book. 2003;Thomson PDR, Montvale, NJ